JPMorgan upgraded HENGRUI PHARMA's rating from Hold to Overweight due to the belief that its current valuation does not fully reflect its improving earnings, expanding pipeline value, and long-term business development income, despite macroeconomic challenges and geopolitical tensions affecting the sector.
